G. Allali

Discipline

Psychologie (19) Science politique (3) Sociologie (2) Linguistique (1)

Type de document

Articles (39) Recensions (6)

Co-auteur

Date

Source

Mot-clé

Human beings (19) Patients (16) Patients (15) risque (11) Risk (11) Disabilities (11) infection (10) Infection (10) maladie (10) maladie (9) Dementia (9) Brain (9) Older people (9) cerveau (9) Time (8) Impact (8) temps (durée) (7) mise sous écran protecteur (7) association (7) âge (7) Social groups (7) Months (7) Evaluation (7) Cognition (7) Age (7) Age (7) cohorte (7) test (6) analyse (6) épidémiologie (6)

Documents écrit par G. Allali (39) | parle de G. Allali (0)

Antidepressants and the risk of bleeding in the era of anti-amyloid drugs.
B. Pozuelo Moyano et al.
Prise en charge pratique de l’affection post-Covid-19. Mise à jour et illustration par des situations cliniques [Practical management of post-COVID-19 condition. Update and illustration by clinical situations]
I. Kokkinakis et al. (8 nov. 2023)
Don't forget primary progressive aphasia for anti-amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry.
A. Hausmann et al.
Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?
G. Breville et al. (27 sept. 2023)
Corrigendum to "Acute TNFα levels predict cognitive impairment 6-9 months after COVID-19 infection" [Psychoneuroendocrinology 153 (2023) 106104].
A. Nuber-Champier et al.
A Pivotal Time.
G. Allali
Personality as a Predictor of Disability in Multiple Sclerosis.
I. Jacot de Alcântara et al. (25 juil. 2023)
Acute TNFα levels predict cognitive impairment 6-9 months after COVID-19 infection.
A. Nuber-Champier et al.
The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review.
M. Jreige et al.
Complications neuropsychiatriques du Covid long
G. Allali et al. (17 mai 2023)
Essais pharmacologiques sur les traitements des symptômes neuropsychiatriques du post-Covid. Revue narrative de la littérature [Pharmacological trials evaluating treatment options for neuropsychiatric symptoms in post-COVID. A narrative review]
N. Lejay et al. (17 mai 2023)
Tauopathies, motricité et cognition [Tauopathy, motricity and cognition]
H. Kermorvant et al. (26 avr. 2023)
Avec le temps, tous les chemins mènent à la neurologie cognitive.
F. Assal et al. (26 avr. 2023)
The Two-Way Route between Delirium Disorder and Dementia: Insights from COVID-19.
G. Bommarito et al.
Brain functional connectivity alterations associated with neuropsychological performance 6-9 months following SARS-CoV-2 infection.
P. Voruz et al.
Neurologie : ce qui a changé en 2022 [Neurology: what's new in 2022]
C. Bouvy et al. (18 janv. 2023)
Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments.
C. Vandersteen et al. (2023)
Increased prevalence of normal pressure hydrocephalus in both variants of frontotemporal dementia: a 10-year retrospective study.
B. Pizzarotti et al. (2023)
Markers of limbic system damage following SARS-CoV-2 infection.
M. Thomasson et al. (2023)
Monocytosis in the acute phase of SARS-CoV-2 infection predicts the presence of anosognosia for cognitive deficits in the chronic phase.
A. Nuber-Champier et al.
Impact of Subjective Evaluations in Predicting Response to Ventriculoperitoneal Shunt for Idiopathic Normal Pressure Hydrocephalus.
M. Messerer et al.
CSF tap test in idiopathic normal pressure hydrocephalus: still a necessary prognostic test?
A. Griffa et al.
The prevention of major neurocognitive disorders in the next phase of COVID-19 pandemic: On being proactive.
O. Beauchet et al.
Using Interaction between Cognitive and Motor Impairment for Risk Screening of Major Neurocognitive Disorders: Results of the EPIDOS Observational Cohort Study.
O. Beauchet et al. (31 juil. 2022)
One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals.
M. Nehme et al.

next